ROCA Test International Expansion

About abcodia

Abcodia, founded in 2009, commercializes the ROCA Test, a proprietary blood test for ovarian cancer surveillance in high-risk women. The test, which tracks changes in the CA-125 biomarker over time using a statistical algorithm, is supported by strong clinical data showing earlier detection and improved surgical outcomes. The company has achieved key validation through NICE guidance and NHS adoption in specific regions, while also expanding access privately and internationally through partnerships. Its business model is centered on providing a diagnostic service to a well-defined, high-risk patient population.

Therapeutic Areas

Other Ovarian Cancer Surveillance Drugs